While recent clinical trials of innovative, new gene therapies show incredible promise for patients who have faced a lifetime of unmet medical needs, the biggest challenge for these therapies is yet to come – ensuring equitable access.

A critical moment for this issue could be the development of new therapies for sickle cell disease, which affects approximately one in 365 Black Americans. What can the life sciences do to ensure that all patients have access to what could be life-changing medicines?

In this month’s Make Shift Happen, panelists from the gene therapy sector and patient advocacy space will discuss:

• The current state of ED&I in therapeutic development
• Taking a patient-centric approach to developing new gene therapies
• Challenges and opportunities for improving therapeutic accessibility